Welcome to Markets Desk, your midday read on what's moving markets and why.
SK Hynix is the name on every trader's screen this morning. The South Korean chipmaker, up nearly eight hundred percent on the back of the AI boom, is set to debut on the Nasdaq and raise roughly twenty-nine billion dollars — potentially the largest U.S. listing ever by a foreign company. How it trades out of the gate will tell us a great deal about whether institutional appetite for AI infrastructure names remains intact or is finally starting to cool.
Staying in biotech, Revolution Medicines has been one of the standout stories of two thousand twenty six, up nearly one hundred forty percent year-to-date on the strength of its targeted cancer therapy pipeline. The question investors are wrestling with now is whether that kind of run has already priced in the good news, or whether the science still justifies adding exposure at current levels. Valuation discipline matters here.
And stepping back to the broader tape, a warning signal that analysts are calling historic is drawing attention — though the underlying thesis amounts to this: nobody actually knows where equities go next. That caveat should travel with every bearish call you hear right now.
That's the tape. Markets Desk, signing off the floor.
